68ga-nota-ae105

Small moleculeexperimentalImaging agent

Clinical trial activity

12 trials · 3 clinical orgs · 0 marketing orgs

Phase 1
2
Phase 2
10
Phase 3
0
Phase 4
0

Earliest trial started May 31, 2014 (NCT02139371)

Timeline

2010s

  1. Jan 1, 2014

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2016

    Earliest Phase 2 Sponsor(trial)

Indications

Mechanism of action

  • Unspecified targetRadiopharmaceutical

    radiopharmaceutical

Chemistry & pharmacology

Imaging
68-gallium

Oral

No

Parenteral

No

Topical

No

Also known as

  • 68ga-nota-ae105

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT06474806Phase 2Jun 1, 2024ABX-CRO, Curasight
NCT03307460Phase 2Nov 21, 2017University of Copenhagen
NCT03278275Phase 2Nov 20, 2017University of Copenhagen
NCT02964988Phase 2Jan 1, 2017University of Copenhagen
NCT02945826Phase 2Jan 1, 2017University of Copenhagen
NCT02960724Phase 2Nov 30, 2016University of Copenhagen
NCT02965001Phase 2Nov 1, 2016University of Copenhagen
NCT02805608Phase 2Sep 1, 2016University of Copenhagen
NCT02755675Phase 2Apr 30, 2016University of Copenhagen
NCT02681640Phase 2Mar 31, 2016University of Copenhagen
NCT02437539Phase 1May 1, 2015Curasight, University of Copenhagen
NCT02139371Early Phase 1 (Phase 1)May 31, 2014University of Copenhagen
Showing 12 of 12 trials
Page 1 / 1

Organizations

Research & Development (3)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
University of CopenhagenAcademic/Hospital111122014
CurasightFor profit2122015
ABX-CROFor profit1012024
3 organizations
Page 1 / 1